Spark Therapeutics Now Targets 2017 For US Approval Of First Retinal Gene Therapy
Executive Summary
Two manufacturing control assays have taken longer to develop than previously thought, putting back completion of a BLA submission to early 2017 for US company Spark Therapeutics, while further progress has been made in the company’s early-stage hemophilia gene therapy program.